Documentaries, videos and podcasts
July 2, 2021
A multi-million-dollar redevelopment on Roebuck Bay leaves long-term caravan park residents feeling nervous about their futures.
May 4, 2021
Faze Medicines , a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Douglas Kerr, M.D., Ph.D., to its board of directors.
Amirah Al Idrus
March 18, 2021
Mark Rus, formerly Shire's group vice president of neuroscience, is taking the helm at Delix Therapeutics, a biotech developing drugs that target neuroplasticity to treat central nervous system disorders. He arrives at Delix after a stint at Atlas Venture, where he led work on an early-stage, neuropsychiatry startup as an entrepreneur in residence.
February 18, 2021
The 240-year old biopharma company reinforced its global ambition in 2019 with the $62 billion acquisition of pharma firm Shire
Research and Markets
February 17, 2021
/PRNewswire/ -- The "Dry Eye Medication Global Market Report 2020-30: COVID-19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering....
Amirah Al Idrus
January 25, 2021
Faze Medicines has a new CEO: Philip Vickers, Ph.D., a Shire alum who most recently led cancer-focused Northern Biologics. Vickers takes over from interim CEO Cary Pfeffer six weeks after Faze emerged with $81 million to pursue medicines targeting biomolecular condensates.
October 9, 2019
Residents in one of Australia's most famous gold rush towns are divided over plans to explore for the precious metal beneath its streets, amid record prices for gold which have injected new life into Coolgardie.
An appeals court on Monday upheld a judge's decision dismissing a lawsuit filed by the U.S. Federal Trade Commission to fight the practice of brand-name drug companies using a government petition system to delay cheaper, generic drugs from coming to market.
January 8, 2019
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) ("Takeda") today announced the completion of its acquisition of Shire plc ("Shire"), becoming a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. Takeda now has an attractive, expanded geographic footprint and leading position in Japan and the U.S., bringing its highly-innovative medicines to approximately 80 countries/regions with dedicated employees worldwide. Takeda's R&D efforts are focused on...
Takeda Pharmaceutical <4502.T> shareholders approved on Wednesday its $59 billion takeover of London-listed Shire , creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt.
November 5, 2018
The boss of Japan's Takeda Pharmaceutical <4502.T> said on Monday he was confident of securing investor backing for its $62 billion acquisition of London-listed Shire , despite some shareholders' fears about the resulting debt burden.